» Articles » PMID: 33262686

Genetic Polymorphism of Is Associated With the Risk of Epilepsy and Predisposition to Neurologic Comorbidity in Chinese Southern Children

Overview
Journal Front Neurosci
Date 2020 Dec 2
PMID 33262686
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Epilepsy, a common disorder of the brain, exhibits a high morbidity rate in children. Childhood epilepsy (CE) is frequently comorbid with neurologic and developmental disorders, sharing underlying genetic factors. This study aimed to investigate the impact of , , and gene polymorphisms on the risk of childhood epilepsy and their associations with predisposition to epileptic comorbidities. A total of 444 children were enrolled in this study, and three single nucleotide polymorphisms, including rs2298383, rs6265, and rs1778929, were genotyped. The frequency distribution of genotypes was compared not only between CE patients and healthy children but also between CE patients with and without comorbidities. The results indicated that the carriers of rs2298383 TT genotype tended to have a lower risk of epilepsy (OR = 0.48, 95% CI = 0.30-0.76), while the CT genotype was related to a higher risk (OR = 1.56, 95% CI = 1.06-2.27). The rs2298383 CC genotype predisposed CE patients to comorbid neurologic disorders (OR = 2.76, 95% CI = 1.31-5.80). Genetic variations in rs6265 and rs1778929 had no significant association with CE and its comorbidities. Fourteen ADORA2A target genes related to epilepsy were identified by the protein-protein interaction analysis, which were mainly involved in the biological processes of "negative regulation of neuron death" and "purine nucleoside biosynthetic process" through the gene functional enrichment analysis. Our study revealed that the genetic polymorphism of rs2298383 was associated with CE risk and predisposition to neurologic comorbidity in children with epilepsy, and the involved mechanism might be related to the regulation of neuron death and purine nucleoside biosynthesis.

Citing Articles

Psychiatric Symptoms in Wilson's Disease-Consequence of Gene Mutations or Just Coincidence?-Possible Causal Cascades and Molecular Pathways.

Gromadzka G, Antos A, Sorysz Z, Litwin T Int J Mol Sci. 2024; 25(22).

PMID: 39596417 PMC: 11595239. DOI: 10.3390/ijms252212354.


Caffeine Consumption and Interaction with ADORA2A, CYP1A2 and NOS1 Variants Do Not Influence Age at Onset of Machado-Joseph Disease.

Martins A, Pinheiro J, Szinwelski L, Cidade E, Santin D, Proenca L Cerebellum. 2024; 23(6):2217-2225.

PMID: 38969840 DOI: 10.1007/s12311-024-01717-7.


Association of ABCB1 Polymorphisms with Efficacy and Adverse Drug Reactions of Valproic Acid in Children with Epilepsy.

Zhu J, Lu J, He Y, Shen X, Xia H, Li W Pharmaceuticals (Basel). 2023; 16(11).

PMID: 38004402 PMC: 10675623. DOI: 10.3390/ph16111536.


Identification of lncRNA-miRNA-mRNA Networks in the Lenticular Nucleus Region of the Brain Contributes to Hepatolenticular Degeneration Pathogenesis and Therapy.

Hao W, Yang W, Yang Y, Cheng T, Wei T, Tang L Mol Neurobiol. 2023; 61(3):1673-1686.

PMID: 37759104 PMC: 10896925. DOI: 10.1007/s12035-023-03631-1.


Association of the ADORA2A receptor and CD73 polymorphisms with epilepsy.

Shi N, Wang Q, Liu J, Zhang J, Deng B, Hu X Front Pharmacol. 2023; 14:1152667.

PMID: 37063258 PMC: 10090369. DOI: 10.3389/fphar.2023.1152667.


References
1.
Kanemoto K, Kawasaki J, Tarao Y, Kumaki T, Oshima T, Kaji R . Association of partial epilepsy with brain-derived neurotrophic factor (BDNF) gene polymorphisms. Epilepsy Res. 2003; 53(3):255-8. DOI: 10.1016/s0920-1211(03)00032-9. View

2.
Sharma P, Kumar A, Singh D . Dietary Flavonoids Interaction with CREB-BDNF Pathway: An Unconventional Approach for Comprehensive Management of Epilepsy. Curr Neuropharmacol. 2019; 17(12):1158-1175. PMC: 7057203. DOI: 10.2174/1570159X17666190809165549. View

3.
Huang J, He Y, Chen M, Du J, Li G, Li S . Adenosine deaminase and adenosine kinase expression in human glioma and their correlation with glioma‑associated epilepsy. Mol Med Rep. 2015; 12(5):6509-16. PMC: 4626129. DOI: 10.3892/mmr.2015.4285. View

4.
Fassio A, Esposito A, Kato M, Saitsu H, Mei D, Marini C . De novo mutations of the ATP6V1A gene cause developmental encephalopathy with epilepsy. Brain. 2018; 141(6):1703-1718. PMC: 5972584. DOI: 10.1093/brain/awy092. View

5.
Loscher W, Klotz U, Zimprich F, Schmidt D . The clinical impact of pharmacogenetics on the treatment of epilepsy. Epilepsia. 2008; 50(1):1-23. DOI: 10.1111/j.1528-1167.2008.01716.x. View